TransCode Therapeutics (NASDAQ:RNAZ) Shares Up 0.9% – Here’s Why

TransCode Therapeutics Inc. (NASDAQ:RNAZ) shot up 0.9% on Friday . The stock traded as high as $8.80 and last traded at $8.64. 4,447 shares traded hands during mid-day trading, a decline of 71% from the average session volume of 15,483 shares. The stock had previously closed at $8.56.

Analyst Upgrades and Downgrades

RNAZ has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of TransCode Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 30th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, TransCode Therapeutics currently has an average rating of “Hold” and an average target price of $280.00.

TransCode Therapeutics Trading Up 0.9%

The company has a market cap of $7.95 million, a PE ratio of -0.32 and a beta of 1.51. The company has a fifty day simple moving average of $11.36 and a two-hundred day simple moving average of $9.94.

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earnings data on Friday, November 14th. The company reported ($5.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.24) by $3.75. On average, research analysts anticipate that TransCode Therapeutics Inc. will post -4.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Warberg Asset Management LLC acquired a new stake in TransCode Therapeutics Inc. (NASDAQ:RNAZ) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 50,000 shares of the company’s stock, valued at approximately $25,000. Warberg Asset Management LLC owned approximately 0.21% of TransCode Therapeutics at the end of the most recent quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.